Open AccessHistone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells
Author(s) -
Sung Victoria,
Richard Normand,
Brady Helen,
Maier Armin,
Kelter Gerhard,
Heise Carla
Publication year - 2011
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2011.01921.x
Subject(s) - gemcitabine , histone deacetylase inhibitor , histone deacetylase , pancreatic cancer , cancer research , chemistry , cell growth , cell cycle , pharmacology , histone , biology , cell , cancer , medicine , biochemistry , gene
Histone deacetylase inhibitors are a group of recently developed compounds that modulate cell growth and survival. We evaluated the effects of the histone deacetylase inhibitor MGCD0103 on growth of pancreatic carcinoma models following single agent treatment and in combination with gemcitabine. MGCD0103 inhibited tumor cell growth and acted synergistically with gemcitabine to enhance its cytotoxic effects. Gene expression analysis identified the cell cycle pathway as one of the most highly modulated gene groups. Our data suggest that MGCD0103 + gemcitabine might be an effective treatment for gemcitabine‐refractory pancreatic cancer. ( Cancer Sci 2011; 102: 1201–1207)